Benoquin Cream 20% is exclusively intended for external use. It's crucial to note that following treatment with Benoquin Cream 20%, the skin will retain heightened sensitivity for the patient's lifetime. Therefore, it is imperative for individuals undergoing this therapy to consistently utilize sunscreens when exposed to sunlight.
Patient Information
Benoquin Cream 20% is formulated with a potent depigmenting agent and should not be mistaken for a cosmetic skin bleach. Its usage is strictly contraindicated for conditions other than disseminated vitiligo. This cream should be employed solely for achieving final depigmentation in cases of extensive vitiligo.
It's noteworthy that areas of normal skin distant from the application site of Benoquin Cream 20% may also undergo depigmentation. Furthermore, irregular, excessive, unsightly, and potentially permanent depigmentation may manifest as a result of its application.
These instructions are paramount for ensuring safe and effective utilization of Benoquin Cream 20%, emphasizing its specific purpose and potential outcomes.
Benoquin is Monobenzone 20 % Cream and used in Vitiligo treatment as Depigmentation agent.

Benoquin: Understanding its Composition and Pharmacology
Benoquin, also known as Monobenzone, constitutes the monobenzyl ether of hydroquinone. It manifests as a white, nearly tasteless crystalline powder, exhibiting solubility in alcohol while being largely insoluble in water.
Chemically identified as p-(benzyloxy) phenol, it bears the empirical formula C13H12O2 with a molecular weight of 200.24. Its structural depiction is as follows:
[Insert Structural Formula Image Here]
Each gram of Benoquin Cream comprises 200 mg of monobenzone USP, dissolved within a water-washable base consisting of purified water USP, cetyl alcohol NF, propylene glycol USP, sodium lauryl sulfate NF, and white wax NF.
Clinical Pharmacology of Benoquin
Benoquin Cream 20% operates as a depigmenting agent, although its precise mechanism remains incompletely elucidated.
In animals, the topical application of monobenzone triggers heightened excretion of melanin from melanocytes. This mechanism is purportedly responsible for the depigmentation observed in human subjects. Monobenzone may induce melanocyte destruction, resulting in enduring depigmentation. This effect exhibits variability and may manifest over a span of one to four months, during which existing melanin is shed along with the normal sloughing of the stratum corneum. Notably, hyperpigmented skin tends to fade more rapidly compared to normal skin, with sunlight exposure diminishing the depigmenting efficacy of the drug. Histological examination of skin post-depigmentation with topical monobenzone mirrors that seen in vitiligo, wherein the epidermis remains unaltered except for the absence of identifiable melanocytes.
This revised rendition aims to succinctly capture the essence of Benoquin's composition and its pharmacological actions.

Benoquin Cream 20% serves as a specialized treatment for achieving final depigmentation in cases of extensive Vitiligo.
Specifically, Benoquin Cream 20% is topically applied to achieve permanent depigmentation of normal skin surrounding vitiliginous lesions in individuals afflicted with disseminated idiopathic vitiligo, where the condition affects more than 50 percent of the body surface area.
It is important to note that Benoquin Cream 20% is not recommended for use in conditions such as freckling, hyperpigmentation induced by photosensitization following the application of certain perfumes (berlock dermatitis), melasma (chloasma) occurring during pregnancy, or hyperpigmentation stemming from skin inflammation. Moreover, its efficacy is not established for treating cafe-au-lait spots, pigmented nevi, malignant melanoma, or pigmentation resulting from substances other than melanin (such as bile, silver, or artificial pigments).
This delineation underscores the targeted application and limitations of Benoquin Cream 20%, emphasizing its role in addressing specific manifestations of vitiligo while cautioning against its use in other dermatological conditions.